The biggest advancements in acute myeloid leukemia medication over the past decade are drugs matched to the leukemia’s genetic makeup. Alongside standard chemotherapy, doctors can now use FLT3 inhibitors, IDH inhibitors, menin inhibitors, the BCL-2 inhibitor venetoclax, and antibody-based drugs. For many patients, especially older adults who cannot tolerate intensive chemotherapy, these options have changed what treatment looks like.
This overview explains how AML develops, how it is diagnosed, and where each newer medicine fits, written for patients and families as well as students and clinicians.
What Is Acute Myeloid Leukemia?
Acute myeloid leukemia (AML) is a fast-growing cancer of the bone marrow. Immature myeloid cells called blasts multiply out of control and crowd out the normal cells that make red cells, infection-fighting white cells, and platelets. It is one of the main types covered in our leukemia guide.
AML arises from acquired genetic changes in blood stem cells. Mutations in genes such as FLT3, NPM1, IDH1, IDH2, and CEBPA affect how cells grow and die. These same mutations are now the targets of many of the newest medicines.
Risk Factors
- Older age: AML is most common in people over 60.
- Prior blood disorders: such as myelodysplastic syndromes or myeloproliferative neoplasms.
- Previous chemotherapy or radiation for another cancer.
- Exposures: long-term benzene exposure and smoking.
- Genetic conditions: such as Down syndrome.
Symptoms and Diagnosis
Symptoms come from the loss of normal blood cells: fatigue and pallor from anemia, frequent or severe infections from low neutrophils, and easy bruising or bleeding from low platelets. Symptoms often develop over just a few weeks.
Diagnosis begins with a complete blood count and blood smear, followed by bone marrow aspiration and biopsy. A marrow blast count of 20% or more is the traditional threshold for AML, although certain genetic changes allow the diagnosis at lower counts. Flow cytometry, chromosome analysis, and next-generation sequencing then identify the specific mutations, and those results now directly determine which medicine is chosen.
The Foundation: Standard Chemotherapy
Treatment for fit patients traditionally runs in two phases. Induction aims for complete remission, meaning no visible leukemia in the marrow and recovering blood counts. The standard “7+3” regimen combines seven days of cytarabine with three days of an anthracycline such as daunorubicin or idarubicin.
Consolidation follows to prevent relapse, using courses of high-dose cytarabine or an allogeneic stem cell transplant for patients at higher risk of relapse. For AML arising from prior therapy or myelodysplasia, a liposomal combination of daunorubicin and cytarabine (CPX-351) is an established option.
Targeted Therapies: Medicines Matched to Mutations
Targeted drugs block the specific abnormal proteins that drive a patient’s leukemia. The table summarizes the main approved classes.
| Target | Examples | Typical use |
|---|---|---|
| FLT3 mutation | Midostaurin, quizartinib, gilteritinib | Added to induction chemotherapy (midostaurin, quizartinib); relapsed or refractory disease (gilteritinib) |
| IDH1 mutation | Ivosidenib, olutasidenib | Newly diagnosed unfit patients or relapsed disease |
| IDH2 mutation | Enasidenib | Relapsed or refractory disease |
| KMT2A rearrangement or NPM1 mutation | Menin inhibitors such as revumenib | Relapsed or refractory disease |
| CD33 on blast surface | Gemtuzumab ozogamicin | Added to chemotherapy in selected patients |
| BCL-2 protein | Venetoclax | With azacitidine, decitabine, or low-dose cytarabine for patients unfit for intensive therapy |
FLT3 Inhibitors
FLT3 mutations, especially the internal tandem duplication form, are linked with aggressive disease and higher relapse risk. Our article on FLT3-ITD positive acute myeloid leukemia covers this subtype in detail. Adding a FLT3 inhibitor to chemotherapy, and sometimes continuing it as maintenance, has become standard for these patients.
IDH and Menin Inhibitors
IDH1 and IDH2 inhibitors work differently from chemotherapy: they allow stuck leukemic cells to mature into normal-looking cells. A side effect called differentiation syndrome, with fever, breathing difficulty, and fluid build-up, can occur and needs prompt treatment, usually with steroids. Menin inhibitors act in a similar way on leukemias driven by KMT2A rearrangements or NPM1 mutations and carry the same risk.
A Special Case: Acute Promyelocytic Leukemia
Acute promyelocytic leukemia (APL) is a subtype of AML defined by a swap between chromosomes 15 and 17 that creates the PML-RARA gene. It was the first form of AML to be transformed by targeted medication. All-trans retinoic acid (ATRA) combined with arsenic trioxide allows the leukemic cells to mature, and for most patients with lower-risk disease this combination cures APL without conventional chemotherapy. APL can cause dangerous bleeding at diagnosis, so ATRA is started as soon as the diagnosis is suspected.
Venetoclax and Lower-Intensity Treatment
For many older or frailer patients, intensive chemotherapy is too risky. The combination of venetoclax with a hypomethylating agent (azacitidine or decitabine) has become a standard approach for this group. It is given largely in outpatient cycles, though low blood counts and infections still need close monitoring.
Oral azacitidine is also used as maintenance therapy for some patients in remission who are not proceeding to transplant.
What Research Is Exploring
Areas under active study include antibody therapies that engage the immune system, CAR T-cell approaches adapted for AML, new drug combinations built on venetoclax, and more sensitive tests for measurable residual disease that detect tiny numbers of leukemia cells after treatment. These remain investigational unless a clinical trial or regulator says otherwise, and your hematologist can advise whether a trial suits you.
When to Contact Your Care Team
Whatever medication you are receiving, some symptoms need a same-day call or an emergency visit:
- A temperature of 38 degrees Celsius (100.4 degrees Fahrenheit) or higher, or shivering
- New bleeding, blood blisters in the mouth, or widespread bruising
- Sudden shortness of breath, chest pain, or rapid weight gain from fluid
- Severe diarrhea, vomiting, or being unable to take your oral medicines
Keep an up-to-date list of every medicine you take, because several targeted AML drugs interact with common antifungals and antibiotics.
Key Takeaways
- Genetic testing of the marrow at diagnosis now guides AML medication choices.
- Standard chemotherapy remains the backbone for fit patients, with targeted drugs added based on mutations.
- FLT3, IDH, and menin inhibitors, venetoclax, and gemtuzumab ozogamicin are key advances.
- Lower-intensity venetoclax combinations have widened options for older adults.
Frequently Asked Questions
Is AML curable with the new medications?
Some patients, particularly younger people with favorable genetic features, are cured with chemotherapy with or without transplant. Newer medicines improve the odds for certain subgroups and extend control of the disease for others, but outcomes vary widely by age and genetics.
Why do I need to wait for genetic results before treatment?
Mutation results, which usually return within days, decide whether a targeted drug should be added from the start. Your team will start supportive care immediately and weigh the urgency of beginning treatment against waiting for these results.
Are targeted AML drugs taken as pills?
Many are. FLT3, IDH, and menin inhibitors and venetoclax are taken by mouth, while chemotherapy, hypomethylating agents, and antibody drugs are usually given by injection or infusion.
What side effects should I watch for?
Fever, bleeding, and signs of infection matter with any AML treatment. With IDH or menin inhibitors, report sudden breathlessness, swelling, or fever promptly, as these can signal differentiation syndrome.
